LATAM is evolving to electronic safety reporting. At this point it looks like there will be some common systems across countries and one of these is VigiFlow.
In Brazil ANVISA (Agência Nacional de Vigilância Sanitária) has committed to implementing all Tier 2 guidance in 2021 and recently announced they will be validating, through a pilot test process, a module in Vigiflow designed for pharmaceutical companies, which is available from October 2020.
Mexico’s COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) has also gone down the route of conducting a pilot phase called “Industry eReporting” which aims to replace the use of current eReporting for the pharmaceutical industry and CROs.
Argentina’s ANMAT, Administración Nacional de Medicamentos, Alimentos y Tecnología Médica has not yet indicated when it will move towards ICH E2B, but it anticipated that it will follow shortly.
However the first country that is already in the process of introducing VigiFlow is Colombia, and it will serve as a learning opportunity for deployment in other countries. Colombia’s INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos, Colombia National Food and Drug Surveillance Institute) was recognised as an ICH (International Council for Harmonisation) regulatory observer at the end of last year. Since then Colombia has complied with ICH standards along with its country regulatory guidance. The latest update came in form of the Tier 2 guidance ICH E2B: Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports. In order to achieve this ICH E2B change in Colombia, INVIMA has identified the need to design, plan and purchase a technological solution for the implementation of this guidance. In 2019, INVIMA collaborated with UMC in Uppsala, Sweden on VigiFlow, which is compliant with the international ICH E2B standard. The pilot testing phase is currently open and the authority will mandate E2B submission from Quarter 4, 2020.
Access to VigiFlow is strictly controlled via a licensing fee, however, a country-specific bolt-on system can be developed as an interface to the system. Uppsala Monitoring Committee (UMC) confirmed that there will be two different platforms for report submission for INVIMA safety reporting; one for those companies that are not able to generate E2B XML’s from their safety databases, i.e. mainly smaller companies or investigational sites. This will be a manual, time consuming process for safety information upload that might require additional planning to ensure data quality. A second platform will be available for all other companies for manual uploading of E2B XML’s reports/files, in a more streamlined manner.
Looking at the second option here, XML files are key to a streamlined ICH E2B process and configuration of the company safety database is required to meet the data exchange requirements for ICH E2B R2 and R3. Depending on the country specific interface system, it may allow for direct upload, or upload with manual data entered for particular fields that can support any language specific requirements such as narratives. This last requirement, may entail the need for certified translations and system adjustments.
INVIMA announced that it expected that all companies should have performed all the changes and updates in systems to generate the XML files in English for the initial testing by 13 April 2020. INVIMA then had a second testing phase for submission of XMLs with the verbatim event term and narrative in Spanish.
The ICON pharmacovigilance team was selected to participate in the pilot testing with INVIMA and accordingly our team was able to proactively test with the latest version of the Argus safety database. The ICON team included skilled systems experts and a cross-functional Spanish speaking team based in Mexico and Colombia. We successfully completed testing with INVIMA in both R2 and R3 XML submissions (in English and Spanish) and will continue to participate in the subsequent pilot phases until E2B implementation in Colombia.
The complex nature of regulatory safety reporting requirements demands a high level of expertise, instant access to critical regulatory intelligence and may require lengthy programming and set-up to ensure compliance. ICON’s dedicated pharmacovigilance intelligence team was established over a decade ago, and specialises in the evaluation of safety reporting requirements through daily review of local, regional and country specific regulatory intelligence and has direct, established contact with regulatory authorities.
ICON’s Miriam Zavaleta will be speaking about the imminent changes at the 1er Congreso Latinoamericano de Farmacovigilancia y Tecnovigilancia y XIV Congreso Nacional de Farmacovigilancia y Tecnovigilancia Congress.
For more information on getting ready for the safety reporting changes in LATAM please contact our pharmacovigilance team.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption whitepaper
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel